CARIOUS EFFECTS OF DRUG INDUCED XEROSTOMIA (CEDIX)

描述：（来自摘要）：本研究的重点是口腔干燥症 处方药的影响和后果。该项目是一个 基于人群的回顾性队列研究，以确定和定义 药物性口干与龋齿关系的研究 在55岁以上的成年人中，他们是两个大型HMO之一的成员：Kaiser Permanente 西北区（波特兰OR）和HealthPartners（明尼阿波利斯/圣保罗） 研究是纵向的，将确定剂量水平和发作情况， 药物使用、拔牙率、修复性牙科护理和费用 与口腔干燥药物有关。 (From第27-8页）：该队列包括55岁以上的所有牙科计划成员 1998年12月31日或以上，有资格获得医疗和牙科护理， 1990年11月至1998年12月31日期间，未服用任何药物的患者 截至1990年1月1日的药物治疗，并且在治疗期间至少有一次牙科就诊 期研究分析的数据将主要来自计算机- 为KPNW和HP的计划成员生成管理文件。数据库 将通过审查患者记录来补充和验证信息 以及一份成员抽样调查表。调查将确定 与口干症相关的其他因素和风险增加的信息 龋齿和牙齿脱落，包括吸烟和饮酒，液体摄入， 咖啡因和非处方药口腔干燥的程度不会 通过临床检查量化。每次分发已知的药物 与口干症有关，药物治疗的发作将是 创造使用以前与口干症无关的药物将 也被跟踪，以确定新的关联。对于每个主题， 将创建药物使用概况，并将该概况与 牙科利用率（服务类型和数量以及费用）将 评估。 研究人员估计，他们的研究队列将包括 十万人。

DESCRIPTION: (from the abstract): The focus of this study is the xerostomic effects and consequences of prescription medications. The project is a population-based, retrospective cohort study to determine and define the magnitude of the association between drug-induced xerostomia and dental caries in adults over 55 who are members of one of two large HMOs: Kaiser Permanente Northwest Division (Portland OR) and HealthPartners (Minneapolis/St Paul) The study is longitudinal and will ascertain dosage levels and episodes of medication use, and rates of extractions, restorative dental care, and costs associated with xerostomic medications. (From pg 27-8): The cohort includes all dental plan members who were 55 years or older on 12/31/98, who were eligible for medical and dental care and had a pharmacy benefit between 11/90 to 12/31/98, who were not taking any medications as of 1/1/90, and who had at least one dental visit during the period. The data analyzed for the study will be derived mostly from computer- generated administrative files for plan members of KPNW and HP. The database information will be supplemented and verified by a review of patient records as well as a questionnaire of a sample of members. The survey will ascertain information on other factors associated with xerostomia and an increased risk of caries and tooth loss, including tobacco and alcohol use, fluid intake, caffeine use, and OTC medications. The extent of xerostomia will not be quantified through clinical examinations. For each dispensing of a drug known to be associated with xerostomia, an episode of drug therapy will be created. Use of medications not previously associated with xerostomia will also be tracked, in order to determine new associations. For each subject, a drug use profile will be created, and associations between this profile and dental utilization (type and number of services as well as cost) will be assessed. The investigators estimate that their study cohort will include well over 100,000 people.